New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
05:29 EDTZMH, SYKBiomet reports Q3 adjusted net income $107.3M vs. $94.9M last year
Reports Q4 revenue $822.5M vs. $771.5M last year. The company said knee sales grew 8.4% worldwide, with U.S. growth of 7.7%. Publicly traded peers of Biomet include Zimmer (ZMH) and Stryker (SYK).
News For ZMH;SYK From The Last 14 Days
Check below for free stories on ZMH;SYK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
10:47 EDTZMHZimmer advances following analyst upgrade
Subscribe for More Information
10:01 EDTZMHOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Achillion (ACHN) upgraded to Buy from Hold at Deutsche Bank... CNOOC (CEO) upgraded to Neutral from Underperform at Credit Suisse... Dollar General (DG) upgraded to Buy from Neutral at Sterne Agee... Equity Residential (EQR) upgraded to Hold from Underperform at Jefferies... HMS Holdings (HMSY) upgraded to Overweight from Equal Weight at First Analysis... HP (HPQ) upgraded to Buy from Neutral at Monness Crespi... Halcon Resources (HK) upgraded to Buy from Hold at MLV & Co.... KapStone (KS) upgraded to Buy from Hold at Deutsche Bank... Sportsman's Warehouse (SPWH) upgraded at RW Baird... Westlake Chemical (WLK) upgraded to Neutral from Reduce at SunTrust... WisdomTree (WETF) upgraded to Neutral from Sell at Citigroup... Zimmer (ZMH) upgraded to Outperform from Market Perform at William Blair.
07:04 EDTZMHZimmer upgraded to Outperform from Market Perform at William Blair
William Blair upgraded Zimmer Holdings to Outperform citing the recent pullback in shares and its belief the proposed Biomet acquisition will close.
August 12, 2014
10:00 EDTSYKOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:22 EDTSYKStryker upgraded to Buy from Hold at Needham
Subscribe for More Information
August 7, 2014
13:24 EDTSYKStryker upcoming analyst day may be catalyst for shares, says Argus
Argus believes Stryker is well positioned to post stronger sales and earnings in the second half of the year as new products launch and surgical volume rebounds. The firm thinks the company's analyst day on September 17 could be a catalyst for the shares and it maintains its Buy rating and $102 price target on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use